How is PT-141 (Bremelanotide) administered?
This describes how PT-141 (Bremelanotide) is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous, on a at least 45 min before activity, max 1x per 24h schedule, generally over use as needed, not daily. Specific dosing is individual and beyond general information, and human evidence for PT-141 (Bremelanotide) is limited.
Administration at a glance (reference data)
- Route: Subcutaneous
- Schedule: at least 45 min before activity, max 1x per 24h
- Cycle length: Use as needed, not daily
- Half-life: ~2 hours
References
- Bremelanotide for HSDD in premenopausal women — Kingsberg SA et al., Obstet Gynecol, 2019
- Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide — Simon JA, Kingsberg SA, Portman D, et al.; Journal of Women's Health; 2022
- Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide — Althof S, Derogatis LR, Greenberg S, et al.; Journal of Sexual Medicine; 2019
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on PT-141 (Bremelanotide)
Full PT-141 (Bremelanotide) breakdownPT-141 (Bremelanotide) what it's used forPT-141 (Bremelanotide) side effectsPT-141 (Bremelanotide) mistakes to avoidPT-141 (Bremelanotide) who should avoid itPT-141 (Bremelanotide) half-lifePT-141 (Bremelanotide) how long to workPT-141 (Bremelanotide) legal statusPT-141 (Bremelanotide) how it workspt 141 vs kisspeptinAsk the AI Coach
Last updated 2026-06-15.